Home > Medical Research Archives > Issue 149 > Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes
![](https://esmed.org/wp-content/uploads/2022/12/MRA-cover-150x150.png)
Published in the Medical Research Archives
Nov 2017 Issue
Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes
Published on Nov 15, 2017
DOI
Abstract
Abstract
Choosing an agent for initial or add-on therapy in type 2 diabetes can be overwhelming for clinicians due to the numerous agents available. Patient specific characteristics, such as the presence of obesity or renal complications, further complicate treatment choices. In clinical studies, albiglutide has been compared to placebo, oral diabetes medications, as well as other injectable agents. The most common adverse effects associated with albiglutide are gastrointestinal in nature, an adverse effect which often subsides with continued use. Serious adverse effects, as with all GLP-1RAs, warrant cautious use of albiglutide in certain patient populations. In addition to its proven safety and efficacy profile, albiglutide may afford patients the added benefits of potential weight loss and improved adherence.
Author info
Author Area
Have an article to submit?
Submission Guidelines
Submit a manuscript
Become a member